Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ICLR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -5.782M
March 31, 2026 -6.358M
December 31, 2025 5.320M
September 30, 2025 -272.82M
June 30, 2025 -275.08M
March 31, 2025 -252.83M
December 31, 2024 -387.67M
September 30, 2024 -103.78M
June 30, 2024 -70.43M
March 31, 2024 -263.70M
December 31, 2023 -247.14M
September 30, 2023 -260.26M
June 30, 2023 -175.13M
March 31, 2023 -157.06M
December 31, 2022 -206.49M
September 30, 2022 -159.84M
June 30, 2022 -79.91M
March 31, 2022 -392.51M
December 31, 2021 -564.46M
September 30, 2021 5.540B
June 30, 2021 0.1721M
March 31, 2021 0.00
December 31, 2020 -0.7666M
September 30, 2020 4.104M
June 30, 2020 0.6228M
Date Value
March 31, 2020 -174.28M
December 31, 2019 -4.801M
September 30, 2019 -71.39M
June 30, 2019 -26.22M
March 31, 2019 -21.63M
December 31, 2018 -66.66M
September 30, 2018 1.362M
June 30, 2018 -5.705M
March 31, 2018 -37.52M
December 31, 2017 -17.93M
September 30, 2017 -2.575M
June 30, 2017 -10.29M
March 31, 2017 -93.71M
December 31, 2016 -156.90M
September 30, 2016 61.10M
June 30, 2016 -0.869M
March 31, 2016 5.378M
December 31, 2015 -163.99M
September 30, 2015 68.36M
June 30, 2015 -14.76M
March 31, 2015 30.06M
December 31, 2014 -85.47M
September 30, 2014 -25.64M
June 30, 2014 -9.059M
March 31, 2014 10.55M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
IQVIA Holdings, Inc. -214.00M
Medpace Holdings, Inc. -288.34M
Proteome Sciences Plc --
Champions Oncology, Inc. -0.019M
Avantor, Inc. -112.40M